July 9 (Reuters) - One of the most notorious insider trading schemes in U.S. history has led to a $75 million fight between drugmaker Pfizer and the U.S. Securities and Exchange Commission. That sum ...
Pfizer's acquisition of Seagen just got the green light Bullish options traders are having a field day with Pfizer Inc. (NYSE:PFE), after the pharma company received all the regulatory approvals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results